INHIBITION OF HEMATOPOIETIC PROGENITOR COLONY GROWTH BY A MONOCLONAL-ANTIBODY AGAINST THE TRANSFERRIN RECEPTOR - COMPARISON OF UNCONJUGATED ANTIBODY WITH AN IMMUNOTOXIN CONTAINING RECOMBINANT RICIN-A CHAIN

We studied an immunotoxin consisting of recombinant ricin A chain (rRA) conjugated to 454A12 MoAb, a monoclonal antibody which recognizes an epitope on the human transferrin receptor, and compared the ability of 454A12 MoAb‐rRA immunotoxin to inhibit the growth of erythroid burst‐forming units (BFU‐e) and myeloid colony‐forming units (CFU‐c) with unconjugated 454A12 MoAb. A significant reduction in BFU‐e colony growth was observed at 0.001 μ g/ml of 454A12 MoAb‐rRA versus 0.1 μ g/ml of unconjugated 454A12 MoAb (p = 0.005). Comparison of the effects of 454A12 MoAb‐rRA and 454A12 MoAb on myeloid colony development gave markedly different results. Unconjugated antibody had no effect on CFU‐c colony growth; in contrast, 0.01 μ g/ml of 454A12 MoAb‐rRA reduced the number of colonies from 139 per 1 ± 105 to 75 per 1 ± 103 cells plated (p = 0.0005). No myeloid progenitor colonies developed at 0.1 μg/ml of immunotoxin. These observations suggest that 454A12 MoAb‐rRA inhibits growth by a potent, ricin A chain‐mediated toxic effect on any proliferating cells expressing transferrin receptors, whereas the 454A12 MoAb exerts a selective inhibitory effect primarily on erythroid progenitors by perturbing the transferrin cycle. While growth factor receptors expressed on hematopoietic cells represent promising targets for immunotoxin therapy, our data indicate that an immunotoxin could inhibit cellular proliferation by a different mechanism than the corresponding unconjugated MoAb. Depending on the antibody used, these differences may be important in trials using immunotoxins for in vivo treatment or in vitro purging of malignant hematopoietic cells. Copyright © 1990 AlphaMed Press